Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 418-433

  Li, Bo ^a,e   Gao, Ying ^a,e   Rankin, Gary O ^b   Rojanasakul, Yon ^c   Cutler, Stephen J ^d   Tu, Youying ^e   Chen, Yi Charlie ^a  

^a Alderson Broaddus College   (United States)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d UNIVERSITY OF MISSISSIPPI   (United States)

^e ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle arrest; Chaetoglobosin K; Ovarian cancer; P38; P53

Indexed keywords

ANTINEOPLASTIC AGENT; CHAETOGLOBOSIN K; CYCLIN B1; PROTEIN P53; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; CHAETOGLOBOSINS; CISPLATIN; INDOLE ALKALOID; MESSENGER RNA; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MITOSIS INHIBITION; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLE ALKALOIDS; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84919458956     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.023     Document Type: Article

References (62)

1. Yang Y.I., Kim J.H., Lee K.T., Choi J.H. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Gynecol. Oncol 2011, 123:588-596.
2. Hu W., Wang F., Tang J., Liu X., Yuan Z., Nie C., et al. Proapoptotic protein smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J. Biol. Chem 2012, 287:68-80.
3. Wahl H., Tan L., Griffith K., Choi M., Liu J.R. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol. Oncol 2007, 105:104-112.
4. Hall M.D., Okabe M., Shen D.W., Liang X.J., Gottesman M.M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu. Rev. Pharmacol. Toxicol 2008, 48:495-535.
5. Marzano C., Gandin V., Folda A., Scutari G., Bindoli A., Rigobello M.P. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med 2007, 42:872-881.
6. Buolamwini J.K. Cell cycle molecular targets in novel anticancer drug discovery. Curr. Pharm. Des 2000, 6:379-392.
7. Diaz-Moralli S., Tarrado-Castellarnau M., Miranda A., Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol. Ther 2013, 138:255-271.
8. Kinghorn A.D., Chin Y.W., Swanson S.M. Discovery of natural product anticancer agents from biodiverse organisms. Curr. Opin. Drug Discov. Devel 2009, 12:189-196.
9. Cutler H.G., Crumley F.G., Cox R.H., Cole R.J., Dorner J.W., Springer J.P., et al. Chaetoglobosin K: a new plant growth inhibitor and toxin from Diplodia macropora. J. Agric. Food Chem 1980, 28:139-142.
10. Matesic D.F., Blommel M.L., Sunman J.A., Cutler S.J., Cutler H.G. Prevention of organochlorine-induced inhibition of gap junctional communication by chaetoglobosin K in astrocytes. Cell Biol. Toxicol 2001, 17:395-408.
11. Sidorova T.S., Matesic D.F. Protective effect of the natural product, Chaetoglobosin K, on lindane-and dieldrin-induced changes in astroglia: identification of activated signaling pathways. Pharm. Res 2008, 25:1297-1308.
12. Ali A., Sidorova T.S., Matesic D.F. Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells. Invest. New Drugs 2012, 31:525-534.
13. Luo H., Li B., Li Z., Cutler S.J., Rankin G.O., Chen Y.C. Chaetoglobosin K inhibits tumor angiogenesis through downregulation of vascular epithelial growth factor-binding hypoxia-inducible factor 1α. Anticancer Drugs 2013, 24:715-724.
14. Hajra K.M., Liu J.R. Apoptosome dysfunction in human cancer. Apoptosis 2004, 9:691-704.
15. Circu M.L., Aw T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med 2010, 48:749-762.
16. Sullivan K.D., Gallant-Behm C.L., Henry R.E., Fraikin J.L., Espinosa J.M. The p53 circuit board. Biochim. Biophys. Acta 2012, 1825:229-244.
17. Wu G.S. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol. Ther 2004, 3:156-161.
18. Wilson T.R., Johnston P.G., Longley D.B. Anti-apoptotic mechanisms of drug resistance in cancer. Curr. Cancer Drug Targets 2009, 9:307-319.
19. Brunelle J.K., Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J. Cell Sci 2009, 22:437-441.
20. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13:1899-1911.
21. Tsujimoto Y., Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 2007, 12:835-840.
22. Day T.W., Huang S., Safa A.R. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem. Pharmacol 2008, 76:1694-1704.
23. LaVallee1 T.M., Zhan X.H., Johnson M.S., Herbstritt C.J., Swartz G., Williams M.S., et al. 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003, 63:468-475.
24. Liu T., Hannafon B., Gill L., Kelly W., Benbrook D. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol. Cancer Ther 2007, 6:1814-1822.
25. Özören N., El-Deiry W.S. Cell surface death receptor signaling in normal and cancer cells. Semin. Cancer Biol 2003, 135-147.
26. Wiezorek J., Holland P., Graves J. Death receptor agonists as a targeted therapy for cancer. Clin. Cancer Res 2010, 16:1701-1708.
27. Duiker E.W., Meijer A., van der Bilt A.R., Meersma G.J., Kooi N., van der Zee A.G., et al. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br. J. Cancer 2011, 104:1278-1287.
28. Yu W., Park S.K., Jia L., Tiwary R., Scott W.W., Li J., et al. RRR-c-tocopherol induces human breast cancer cells to undergo apoptosis via death receptor 5 (DR5)-mediated apoptotic signaling. Cancer Lett 2008, 259:165-176.
29. Gabrielli B., Brooks K., Pavey S. Defective cell cycle checkpoints as targets for anti-cancer therapies. Front. Pharmacol 2012, 3-9.
30. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther 2004, 3:513-519.
31. Schonn I., Hennesen J., Dartsch D.C. Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage. Apoptosis 2010, 15:162-172.
32. Ujiki M.B., Ding X.Z., Salabat M.R., Bentrem D.J., Golkar L., Milam B., et al. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer 2006, 5:76.
33. Zhou X., Zheng M., Chen F., Zhu Y., Yong W., Lin H., et al. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. Anat. Rec 2009, 292:1122-1127.
34. O'Brien V., Brown R. Signalling cell cycle arrest and cell death through the MMR system. Carcinogenesis 2006, 27:682-692.
35. Kajstura M., Halicka H.D., Pryjma J., Darzynkiewicz Z. Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete "sub-G1" peaks on DNA content histograms. Cytometry A. 2007, 71:125-131.
36. Grana X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinase s (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CK Is). Oncogene 1995, 11:211-219.
37. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther 2002, 1:639-649.
38. Li W., Fan J., Banerjee D., Bertino J.R. Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol. Pharmacol 1999, 55:1088-1093.
39. Upadhyay S., Neburi M., Chinni S.R., Alhasan S., Miller F., Sarkar F.H. Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21(WAF1). Clin. Cancer Res 2001, 7:1782-1789.
40. Darcy K.M., Brady W.E., McBroom J.W., Bell J.G., Young R.C., McGuire W.P., et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol. Oncol 2008, 111:487-495.
41. Kuo Y.C., Kuo P.L., Hsu Y.L., Cho C.Y., Lin C.C. Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci 2006, 78:2550-2557.
42. Pucci B., Kasten M., Giordano A. Cell cycle and apoptosis. Neoplasia 2000, 2:291-299.
43. Kong D., Ma S., Liang B., Yi H., Zhao Y., Xin R., et al. The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells. Biomed. Pharmacother 2012, 66:271-278.
44. Ashcroft M., Kubbutat M.H.G., Vousden K.H. Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol 1999, 19:1751-1758.
45. Siliciano J.D., Canman C.E., Taya Y., Sakaguchi K., Appella E., Kastan M.B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997, 11:3471-3481.
46. Rong J.J., Hu R., Qi Q., Gu H.Y., Zhao Q., Wang J., et al. Gambogic acid down-regulates MDM2 oncogene and induces p21Waf1/CIP1 expression independent of p53. Cancer Lett 2009, 284:102-112.
47. Brown R., Clugston C., Burns P., Edlin A., Vasey P., Vojtěsek B., et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer 1993, 55:678-684.
48. Yaginuma Y., Westphal H. Abnormal structure and expression of the p53 Gene in human ovarian carcinoma cell lines. Cancer Res 1992, 52:4196-4199.
49. Guan Y.Q., Li Z., Yang A., Huang Z., Zheng Z., Zhang L., et al. Cell cycle arrest and apoptosis of OVCAR-3 and MCF-7 cells induced by co-immobilized TNF-α plus IFN-γ on polystyrene and the role of p53 activation. Biomaterials 2012, 33:6162-6171.
50. Lin H.Y., Delmas D., Vang O., Hsieh T.C., Lin S., Cheng G.Y., et al. Mechanisms of ceramide-induced COX-2-dependent apoptosis in human ovarian cancer OVCAR-3 cells partially overlapped with resveratrol. J. Cell. Biochem 2013, 114:1940-1954.
51. Liu J., Uematsu H., Tsuchida N., Ikeda M.A. Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol. Cancer 2011, 10:95-107.
52. 2 checkpoint through cyclin B1. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:2147-2152.
53. Chen J.J., Chou C.W., Chang Y.F., Chen C.C. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intrinsic regulati on of DR5: involvement of NF-κB and reactive oxygen species-mediated p53 activation. J. Immunol 2008, 180:8030-8039.
54. Yeh C.C., Deng Y.T., Sha D.Y., Hsiao M., Kuo M.Y. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol. Cancer Ther 2009, 8:2718-2725.
55. Lee J.C., Chou L.C., Huang C.H., Chung J.G., Huang L.J., Lee K.H., et al. CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells. Eur. J. Pharmacol 2011, 670:96-104.
56. Shetty S., Graham B.A., Brown J.G., Hu X., Vegh-Yarema N., Harding G., et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol. Cell. Biol 2005, 25:5404-5416.
57. Yi L., Zongyuan Y., Cheng G., Lingyun Z., Guilian Y., Wei G. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci 2014, 10.1111/cas.12395.
58. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
59. Mansouri A., Ridgway L.D., Korapati A.L., Zhang Q., Tian L., Wang Y., et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J. Biol. Chem 2003, 278:19245-19256.
60. Zhang B., Wang X., Cai F., Chen W., Loesch U., Bitzer J., et al. Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK. Tumour Biol 2012, 33:1855-1862.
61. 2 checkpoint elicited by arsenite. J. Cell. Physiol 2007, 212:481-488.
62. Takekawa M., Adachi M., Nakahata A., Nakayama I., Itoh F., Tsukuda H., et al. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 2000, 19:6517-6526.